Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Cefazolin plasma protein binding and its covariates in neonates.

Smits A, Kulo A, Verbesselt R, Naulaers G, de Hoon J, Vermeersch P, Allegaert K.

Eur J Clin Microbiol Infect Dis. 2012 Dec;31(12):3359-65. doi: 10.1007/s10096-012-1703-x. Epub 2012 Jul 26.

PMID:
22833246
2.

Cefazolin plasma protein binding saturability during pregnancy.

Allegaert K, Van Mieghem T, Verbesselt R, Vanhole C, Devlieger R, Cossey V, Deprest J, de Hoon J.

Methods Find Exp Clin Pharmacol. 2009 Jan-Feb;31(1):25-8. doi: 10.1358/mf.2009.31.1.1338413.

PMID:
19357795
3.

Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates.

De Cock RF, Smits A, Allegaert K, de Hoon J, Saegeman V, Danhof M, Knibbe CA.

J Antimicrob Chemother. 2014 May;69(5):1330-8. doi: 10.1093/jac/dkt527. Epub 2014 Feb 2.

PMID:
24492261
4.

Pharmacokinetics and protein binding of cefazolin in morbidly obese patients.

van Kralingen S, Taks M, Diepstraten J, van de Garde EM, van Dongen EP, Wiezer MJ, van Ramshorst B, Vlaminckx B, Deneer VH, Knibbe CA.

Eur J Clin Pharmacol. 2011 Oct;67(10):985-92. doi: 10.1007/s00228-011-1048-x. Epub 2011 Apr 16.

PMID:
21499760
5.

Cefazolin plasma protein binding in different human populations: more than cefazolin-albumin interaction.

Smits A, Roberts JA, Vella-Brincat JW, Allegaert K.

Int J Antimicrob Agents. 2014 Feb;43(2):199-200. doi: 10.1016/j.ijantimicag.2013.10.008. Epub 2013 Nov 8. No abstract available.

PMID:
24359839
6.

Protein binding of cefazolin is saturable in vivo both between and within patients.

Vella-Brincat JW, Begg EJ, Kirkpatrick CM, Zhang M, Chambers ST, Gallagher K.

Br J Clin Pharmacol. 2007 Jun;63(6):753-7. Epub 2007 Jan 12.

7.

Evaluation of total body weight and body mass index cut-offs for increased cefazolin dose for surgical prophylaxis.

Hites M, Deprez G, Wolff F, Ickx B, Verleije A, Closset J, Loi P, Prévost J, Taccone FS, Racapé J, Cotton F, Jacobs F.

Int J Antimicrob Agents. 2016 Dec;48(6):633-640. doi: 10.1016/j.ijantimicag.2016.08.019. Epub 2016 Oct 5.

8.

Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis.

Brill MJ, Houwink AP, Schmidt S, Van Dongen EP, Hazebroek EJ, van Ramshorst B, Deneer VH, Mouton JW, Knibbe CA.

J Antimicrob Chemother. 2014 Mar;69(3):715-23. doi: 10.1093/jac/dkt444. Epub 2013 Nov 8.

PMID:
24214905
9.

Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients.

Roberts JA, Udy AA, Jarrett P, Wallis SC, Hope WW, Sharma R, Kirkpatrick CM, Kruger PS, Roberts MS, Lipman J.

J Antimicrob Chemother. 2015 May;70(5):1495-502. doi: 10.1093/jac/dku564. Epub 2015 Jan 20.

PMID:
25608584
10.

Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block.

Rapp HJ, Molnár V, Austin S, Krohn S, Gädeke V, Motsch J, Boos K, Williams DG, Gustafsson U, Huledal G, Larsson LE.

Paediatr Anaesth. 2004 Sep;14(9):724-32.

PMID:
15330953
11.

Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.

Ulldemolins M, Roberts JA, Wallis SC, Rello J, Lipman J.

J Antimicrob Chemother. 2010 Aug;65(8):1771-8. doi: 10.1093/jac/dkq184. Epub 2010 Jun 8.

PMID:
20530507
12.

Pharmacokinetic modelling of total and unbound plasma carboplatin--a population study in 75 children.

Urien S, Doz F, Namouni F, Bastian G.

Int J Clin Pharmacol Ther. 2002 Jun;40(6):270-8.

PMID:
12078941
13.

Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?

Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, Roberts JA.

Antimicrob Agents Chemother. 2013 Dec;57(12):6165-70. doi: 10.1128/AAC.00951-13. Epub 2013 Sep 30.

14.

Skeletal muscle and plasma concentrations of cefazolin during cardiac surgery in infants.

Himebauch AS, Nicolson SC, Sisko M, Moorthy G, Fuller S, Gaynor JW, Zuppa AF, Fox E, Kilbaugh TJ.

J Thorac Cardiovasc Surg. 2014 Dec;148(6):2634-41. doi: 10.1016/j.jtcvs.2014.06.064. Epub 2014 Jul 22.

15.

Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates.

Pullen J, de Rozario L, Stolk LM, Degraeuwe PL, van Tiel FH, Zimmermann LJ.

Ther Drug Monit. 2006 Jun;28(3):351-8.

PMID:
16778719
17.

Cefazolin bolus and continuous administration for elective cardiac surgery: improved pharmacokinetic and pharmacodynamic parameters.

Adembri C, Ristori R, Chelazzi C, Arrigucci S, Cassetta MI, De Gaudio AR, Novelli A.

J Thorac Cardiovasc Surg. 2010 Aug;140(2):471-5. doi: 10.1016/j.jtcvs.2010.03.038. Epub 2010 Jun 8.

19.

Penetration of antibiotics into the surgical wound in a canine model.

Rosin E, Ebert S, Uphoff TS, Evans MH, Schultz-Darken NJ.

Antimicrob Agents Chemother. 1989 May;33(5):700-4.

20.

Hepatic cyst penetration of cefazolin in patients receiving aspiration sclerotherapy.

Lantinga MA, Wijnands TF, Te Morsche RH, de Sévaux RG, Kuipers S, Allegaert K, Burger D, Drenth JP.

J Antimicrob Chemother. 2016 Sep;71(9):2547-52. doi: 10.1093/jac/dkw172. Epub 2016 May 30.

PMID:
27246239

Supplemental Content

Support Center